X-linked chronic granulomatous disease (X-CGD) is a rare genetic disorder, which affects boys. It is caused by an error in a gene that makes part of the immune system. The basic defect lies in specialised white blood cells called phagocytic cells (or phagocytes), which are responsible for protection against infection by destroying invading bacteria and fungi. They do this by pouring large amounts of substances similar to bleach onto these organisms. In CGD, there is a defect in the system that makes the bleach, called the NADPH-oxidase. In X-CGD (which accounts for two thirds of patients), the defect lies in a gene which makes up a critical part of the NADPH-oxidase (known as gp91-phox), and the cells cannot make bleach-like substances. Therefore they kill bacteria and fungi poorly, and the patients suffer from severe and recurrent infections. This also results in inflammation which can damage parts of the body such as the lung and gut. In many cases, patients can be adequately protected from infection by constant intake of antibiotics. However, in others, severe life-threatening infections break through. In some cases, inflammation in the bowel or urinary systems results in blockages which cannot be treated with antibiotics, and which may require the use of other drugs such as steroids. Development of curative treatments for CGD is therefore of great importance.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
3
Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing GP91PHOX gene
University College London Hospital (UCLH)
London, United Kingdom
Great Ormond Street Hospital NHS Foundation Trust
London, United Kingdom
Safety of the procedure as measured by the incidence of adverse events
Time frame: 24 months
Restoration and stability over time of the NADPH functioning granulocytes assessed by a DHR test
Time frame: 12 months
Normalisation of nutritional status, growth, development, severe infection and/or inflammatory complication which recommended patient's inclusion
Time frame: 24 months
Percentage of transduced CD34+ haematopoietic cells infused and of blood cells over time
Time frame: 24 months
Immunological reconstitution
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.